CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc. today announced that new data highlighting the anti-angiogenic and tumor-targeting properties of TM601 will be discussed in a poster presentation and in a published abstract at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held May 29-June 2, 2009 in Orlando, FL. TM601 is a novel, wholly synthetic peptide, found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease.
